SU-DHL-8 Cells

SU-DHL-8 is a human diffuse large B-cell lymphoma (DLBCL) cell line derived from an adult patient. It represents the activated B-cell-like (ABC) subtype of DLBCL, which is characterized by constitutive activation of the NF-κB signaling pathway and typically exhibits poorer prognosis compared to the germinal center B-cell-like (GCB) subtype. Morphologically, the SU-DHL-8 cells grow as large, loosely adherent aggregates in suspension, consistent with B-cell lymphoma phenotypes.

Molecular characterization reveals that SU-DHL-8 harbors mutations commonly associated with ABC-DLBCL, including alterations affecting the BCR and NF-κB signaling pathways. Genomic profiling through next-generation sequencing and expression analysis has identified elevated activity in pathways such as JAK/STAT and BCL2-associated anti-apoptotic signaling. The cell line is also part of several large-scale pharmacogenomic studies and cancer model repositories, where it has been used to explore drug sensitivities, particularly to kinase inhibitors and proteasome-targeting agents. These features make SU-DHL-8 a representative and valuable model for investigating the molecular pathogenesis and therapeutic vulnerabilities of ABC-type DLBCL.